{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:21:15Z","timestamp":1790263275002,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111706","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T23:15:01Z","timestamp":1708384501000},"page":"111706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study"],"prefix":"10.1016","volume":"130","author":[{"given":"Young-Min","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Sook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunji","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bomin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Ho","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Sim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2024.111706_b0005","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.intimp.2024.111706_b0010","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","article-title":"Burden of atopic dermatitis in adults and adolescents: a systematic literature review","volume":"12","author":"Fasseeh","year":"2022","journal-title":"Dermatol Ther (heidelb)"},{"issue":"6","key":"10.1016\/j.intimp.2024.111706_b0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5021\/ad.21.239","article-title":"Assessment of disease severity and quality of life in patients with atopic dermatitis from south korea","volume":"34","author":"Son","year":"2022","journal-title":"Ann Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111706_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ada.2022.119009","article-title":"The increase in allergic conditions based on a review of literature","volume":"40","author":"Gutowska-Slesik","year":"2023","journal-title":"Postepy Dermatol Alergol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2024.111706_b0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12026-009-8160-3","article-title":"IgE antibody-specific activity in human allergic disease","volume":"47","author":"Hamilton","year":"2010","journal-title":"Immunol Res."},{"issue":"6793","key":"10.1016\/j.intimp.2024.111706_b0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/35018500","article-title":"Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha","volume":"406","author":"Garman","year":"2000","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.intimp.2024.111706_b0035","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.str.2006.03.017","article-title":"Structural changes in the lectin domain of CD23, the low-affinity IgE receptor, upon calcium binding","volume":"14","author":"Wurzburg","year":"2006","journal-title":"Structure."},{"issue":"5","key":"10.1016\/j.intimp.2024.111706_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nri2072","article-title":"New developments in FcepsilonRI regulation, function and inhibition","volume":"7","author":"Kraft","year":"2007","journal-title":"Nat Rev Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.111706_b0045","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cells8090994","article-title":"Tracing IgE-Producing Cells in Allergic Patients","volume":"8","author":"Eckl-Dorna","year":"2019","journal-title":"Cells."},{"issue":"6","key":"10.1016\/j.intimp.2024.111706_b0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/all.13119","article-title":"AllergoOncology - the impact of allergy in oncology: EAACI position paper","volume":"72","author":"Jensen-Jarolim","year":"2017","journal-title":"Allergy."},{"key":"10.1016\/j.intimp.2024.111706_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2018.05.015","article-title":"Approaches to target IgE antibodies in allergic diseases","volume":"191","author":"Balbino","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.intimp.2024.111706_b0060","unstructured":"US Food and Drug Administration, XOLAIR: Full prescribing information, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/103976Orig1s5243lbl.pdf. (Accessed 16 October 2023)."},{"issue":"1","key":"10.1016\/j.intimp.2024.111706_b0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun."},{"issue":"14","key":"10.1016\/j.intimp.2024.111706_b0070","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.intimp.2024.111706_b0075","doi-asserted-by":"crossref","first-page":"AB130","DOI":"10.1016\/j.jaci.2022.12.410","article-title":"Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: results from the Phase-3 Pivotal Trials","volume":"151","author":"Ensina","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10422","key":"10.1016\/j.intimp.2024.111706_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2024.111706_b0085","doi-asserted-by":"crossref","first-page":"e1225","DOI":"10.1002\/cti2.1255","article-title":"Ligelizumab treatment for severe asthma: learnings from the clinical development programme","volume":"10","author":"Trischler","year":"2021","journal-title":"Clin & Trans Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.111706_b0090","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1038\/s41467-022-33176-1","article-title":"Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy","volume":"13","author":"An","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.intimp.2024.111706_b0095","unstructured":"Lee, K.W., Yang, B-G., Oh, E.Y., Park, K.H., Ryu, M.S., et al., GI-301, a novel long-acting IgETrap-Fc fusion protein with durable and high binding to IgE translates therapeutic efficacy in various animal models (Poster), (Urticaria Conference 2019)."},{"issue":"1","key":"10.1016\/j.intimp.2024.111706_b0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.anai.2021.03.023","article-title":"Serum-free immunoglobulin E: a useful biomarker of atopy and type 2 asthma in adults with asthma","volume":"127","author":"Woo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.111706_b0105","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1172\/JCI129697","article-title":"The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcgamma receptors","volume":"130","author":"Balbino","year":"2020","journal-title":"J Clin Invest"},{"issue":"500","key":"10.1016\/j.intimp.2024.111706_b0110","doi-asserted-by":"crossref","first-page":"eaat1479","DOI":"10.1126\/scitranslmed.aat1479","article-title":"An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis","volume":"11","author":"Jonsson","year":"2019","journal-title":"Sci Transl Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.111706_b0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.alit.2017.08.003","article-title":"Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab","volume":"67","author":"Gon","year":"2018","journal-title":"Allergol Int"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.111706_b0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jim.2005.06.008","article-title":"Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy","volume":"303","author":"Hamilton","year":"2005","journal-title":"J Immunol Methods."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2024.111706_b0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2332\/allergolint.13-OA-0643","article-title":"Development of assay for determining free IgE levels in serum from patients treated with omalizumab","volume":"63","author":"Ito","year":"2014","journal-title":"Allergol Int."},{"issue":"11","key":"10.1016\/j.intimp.2024.111706_b0130","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2012.07.010","article-title":"Monitoring free serum IgE in severe asthma patients treated with omalizumab","volume":"106","author":"Korn","year":"2012","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.intimp.2024.111706_b0135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:15:24Z","timestamp":1761588924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924002248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":27,"alternative-id":["S1567576924002248"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111706","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111706"}}